|
1
|
Hoxha E, Wiech T, Stahl PR, Zahner G,
Tomas NM, Meyer-Schwesinger C, Wenzel U, Janneck M, Steinmetz OM,
Panzer U, et al: A mechanism for cancer-associated membranous
nephropathy. N Engl J Med. 374:1995–1996. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
American Society of Clinical Oncology, .
The state of cancer care in America, 2014: A report by the American
Society of Clinical Oncology. J Oncol Pract. 10:119–142. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Moor JS, Mariotto AB, Parry C, Alfano
CM, Padgett L, Kent EE, Forsythe L, Scoppa S, Hachey M and Rowland
JH: Cancer survivors in the United States: Prevalence across the
survivorship trajectory and implications for care. Cancer Epidemiol
Biomarkers Prev. 22:561–570. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
National Cancer Institute, . Chemotherapy
side effects sheets. http://www.cancer.gov/cancertopics/coping/physicaleffects/chemo-side-effectsAccessed.
May 2–2014.
|
|
5
|
Polomano RC and Bennett GJ:
Chemotherapy-evoked painful peripheral neuropathy. Pain Med.
2:8–14. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hershman DL, Lacchetti C, Dworkin RH,
Smith EM Lavoie, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino
A, Lustberg MB, et al: American Society of Clinical Oncology:
Prevention and management of chemotherapy-induced peripheral
neuropathy in survivors of adult cancers: American Society of
Clinical Oncology clinical practice guideline. J Clin Oncol.
32:1941–1967. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fujita Y, Nakamoto A, Inoue M, Hayashi Y,
Shimizu M, Hotta A, Yoshikawa N, Ohira N and Tatekawa S: Anesthetic
management with propofol alone in a patient with hereditary sensory
and autonomic neuropathy. Masui. 65:352–355. 2016.(In Japanese).
PubMed/NCBI
|
|
8
|
Baron R: Mechanisms of disease:
Neuropathic pain - a clinical perspective. Nat Clin Pract Neurol.
2:95–106. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Waxman SG and Zamponi GW: Regulating
excitability of peripheral afferents: Emerging ion channel targets.
Nat Neurosci. 17:153–163. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang Y, Wang Y, Li S, Xu Z, Li H, Ma L,
Fan J, Bu D, Liu B, Fan Z, et al: Mutations in SCN9A, encoding a
sodium channel alpha subunit, in patients with primary
erythermalgia. J Med Genet. 41:171–174. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Faber CG, Lauria G, Merkies IS, Cheng X,
Han C, Ahn HS, Persson AK, Hoeijmakers JG, Gerrits MM, Pierro T, et
al: Gain-of-function Nav1.8 mutations in painful neuropathy. Proc
Natl Acad Sci U S A. 109:19444–19449. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Craner MJ, Klein JP, Renganathan M, Black
JA and Waxman SG: Changes of sodium channel expression in
experimental painful diabetic neuropathy. Ann Neurol. 52:786–792.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alessandri-Haber N, Dina OA, Yeh JJ,
Parada CA, Reichling DB and Levine JD: Transient receptor potential
vanilloid 4 is essential in chemotherapy-induced neuropathic pain
in the rat. J Neurosci. 24:4444–4452. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hudson LJ, Bevan S, Wotherspoon G, Gentry
C, Fox A and Winter J: VR1 protein expression increases in
undamaged DRG neurons after partial nerve injury. Eur J Neurosci.
13:2105–2114. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Herrero JF, Laird JM and López-García JA:
Wind-up of spinal cord neurones and pain sensation: Much ado about
something? Prog Neurobiol. 61:169–203. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Luo ZD, Chaplan SR, Higuera ES, Sorkin LS,
Stauderman KA, Williams ME and Yaksh TL: Upregulation of dorsal
root ganglion (α)2(δ) calcium channel subunit and its correlation
with allodynia in spinal nerve-injured rats. J Neurosci.
21:1868–1875. 2001.PubMed/NCBI
|
|
17
|
Moore KA, Kohno T, Karchewski LA, Scholz
J, Baba H and Woolf CJ: Partial peripheral nerve injury promotes a
selective loss of GABAergic inhibition in the superficial dorsal
horn of the spinal cord. J Neurosci. 22:6724–6731. 2002.PubMed/NCBI
|
|
18
|
Coull JAM, Boudreau D, Bachand K, Prescott
SA, Nault F, Sík A, De Koninck P and De Koninck Y: Trans-synaptic
shift in anion gradient in spinal lamina I neurons as a mechanism
of neuropathic pain. Nature. 424:938–942. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fields HL: Is there a facilitating
component to central pain modulation? APS J. 1:71–78. 1992.
View Article : Google Scholar
|
|
20
|
Saab CY: Pain-related changes in the
brain: diagnostic and therapeutic potentials. Trends Neurosci.
35:629–637. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dray A: Inflammatory mediators of pain. Br
J Anaesth. 75:125–131. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gaudet AD, Popovich PG and Ramer MS:
Wallerian degeneration: Gaining perspective on inflammatory events
after peripheral nerve injury. J Neuroinflammation. 8:1102011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Myers RR, Campana WM and Shubayev VI: The
role of neuroinflammation in neuropathic pain: Mechanisms and
therapeutic targets. Drug Discov Today. 11:8–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brück W and Friede RL: The role of
complement in myelin phagocytosis during PNS wallerian
degeneration. J Neurol Sci. 103:182–187. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
De Jongh RF, Vissers KC, Meert TF, Booij
LHDJ, De Deyne CS and Heylen RJ: The role of interleukin-6 in
nociception and pain. Anesth Analg. 96:1096–1103. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sommer C, Petrausch S, Lindenlaub T and
Toyka KV: Neutralizing antibodies to interleukin 1-receptor reduce
pain associated behavior in mice with experimental neuropathy.
Neurosci Lett. 270:25–28. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
White FA and Wilson NM: Chemokines as pain
mediators and modulators. Curr Opin Anaesthesiol. 21:580–585. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ji RR, Berta T and Nedergaard M: Glia and
pain: Is chronic pain a gliopathy? Pain. 154:(Suppl 1). S10–S28.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Richardson PG, Delforge M, Beksac M, Wen
P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV,
et al: Management of treatment-emergent peripheral neuropathy in
multiple myeloma. Leukemia. 26:595–608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Richardson PG, Barlogie B, Berenson J,
Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina
M, Alexanian R, et al: A phase 2 study of bortezomib in relapsed,
refractory myeloma. N Engl J Med. 348:2609–2617. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Richardson PG, Briemberg H, Jagannath S,
Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D,
Schuster M, et al: Frequency, characteristics, and reversibility of
peripheral neuropathy during treatment of advanced multiple myeloma
with bortezomib. J Clin Oncol. 24:3113–3120. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mohty B, El-Cheikh J, Yakoub-Agha I,
Moreau P, Harousseau JL and Mohty M: Peripheral neuropathy and new
treatments for multiple myeloma: Background and practical
recommendations. Haematologica. 95:311–319. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Usmani SZ, Cavenagh JD, Belch AR, Hulin C,
Basu S, White D, Nooka A, Ervin-Haynes A, Yiu W, Nagarwala Y, et
al: Cost-effectiveness of lenalidomide plus dexamethasone vs.
bortezomib plus melphalan and prednisone in transplant-ineligible
U.S. patients with newly-diagnosed multiple myeloma. J Med Econ.
19:243–258. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Boyette-Davis JA, Cata JP, Zhang H, Driver
LC, Wendelschafer-Crabb G, Kennedy WR and Dougherty PM: Follow-up
psychophysical studies in bortezomib-related chemoneuropathy
patients. J Pain. 12:1017–1024. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Meregalli C, Canta A, Carozzi VA,
Chiorazzi A, Oggioni N, Gilardini A, Ceresa C, Avezza F, Crippa L,
Marmiroli P, et al: Bortezomib-induced painful neuropathy in rats:
a behavioral, neurophysiological and pathological study in rats.
Eur J Pain. 14:343–350. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cavaletti G, Gilardini A, Canta A,
Rigamonti L, Rodriguez- Menendez V, Ceresa C, Marmiroli P, Bossi M,
Oggioni N, D'Incalci M, et al: Bortezomib-induced peripheral
neurotoxicity: A neurophysiological and pathological study in the
rat. Exp Neurol. 204:317–325. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Casafont I, Berciano MT and Lafarga M:
Bortezomib induces the formation of nuclear poly(A) RNA granules
enriched in Sam68 and PABPN1 in sensory ganglia neurons. Neurotox
Res. 17:167–178. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Windebank AJ and Grisold W:
Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 13:27–46.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kyle RA and Rajkumar SV: Multiple myeloma.
N Engl J Med. 351:1860–1873. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Scott K and Kothari MJ: Evaluating the
patient with peripheral nervous system complaints. J Am Osteopath
Assoc. 105:71–83. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Millennium Pharmaceuticals, Inc., .
Highlights of prescribing information. http://www.velcade.com/Files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdfAccessed.
March 20–2014.
|
|
42
|
Cavaletti G and Marmiroli P:
Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol.
6:657–666. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Postma TJ and Heimans JJ: Grading of
chemotherapy-induced peripheral neuropathy. Ann Oncol. 11:509–513.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cornblath DR, Chaudhry V, Carter K, Lee D,
Seysedadr M, Miernicki M and Joh T: Total neuropathy score:
Validation and reliability study. Neurology. 53:1660–1664. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Maier C, Baron R, Tölle TR, Binder A,
Birbaumer N, Birklein F, Gierthmühlen J, Flor H, Geber C, Huge V,
et al: Quantitative sensory testing in the German Research Network
on Neuropathic Pain (DFNS): Somatosensory abnormalities in 1236
patients with different neuropathic pain syndromes. Pain.
150:439–450. 2010. View Article : Google Scholar : PubMed/NCBI
|
